Please login to the form below

Deal Watch table for January 2014

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers agreed during January 2014.

For an indepth analysis of these deals, read 'Pharma deals during January 2014'

Licensor acquired / licensee acquirer	Deal type	Product / technology	Headline ($m)
Edison Pharmaceuticals/ Dainippon Sumitomo Pharma	Strategic alliance	Extends development/ commercialisation* agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs	4,295
Aptalis/ Forest	Company acquisition	Acquiring sales turnover of $688m	2,900
Alnylam/ Genzyme	Extended agreement	Additional markets for patisiran and 3 pipeline products with option to all rare disease products	700
Biogen Idec/ Royalty Pharma	Earn out	Indirect interest in Tecfidera sales in Germany in relapsing forms of MS	510
JHP/ Par Pharmaceuticals	Company acquisition	Par acquires JHP, a leading specialty pharmaceutical company of branded and generic sterile injectables	490
Aerial BioPharma/ Jazz Pharmaceuticals	Product rights	Jazz gain access to ADX N05 for treatment of narcolepsy, SK Biopharmaceuticals retain some Asian rights, upfront of $125m, Aerial and SK receive milestones and royalties	397
Scientific Protein Labs/Shenzhen Hepalink	Company acquisition	API supplier	337.5
Capricor Therapeutics/ Janssen Biotech	Collaboration and exclusive licence option	CAP1002 an allogeneic cardiosphere-derived cell (CDC) therapeutic for treatment of myocardial infarction	337.5
Immunocore/AZ Medimmune	Collaboration and licence	Immune mobilising monoclonal T-Cell receptor against cancer (ImmTAC) therapies	320
Sangamo/Biogen Idec	Collaboration and licence	Development of therapies for haemoglobinopathies using zinc finger genome editing	320
Shire/ Organogenesis	Divestment	Shire's sale of its Dermagraft assets acquired as part of Advanced BioHealing	300
Merck/Alnylam	Divestment	Sale of Merck's RNAi therapeutics unit Sirna	290
Santaris/Roche	Discovery and development	Novel RNA targeted medicines using Santaris' locked nucleic acid drug platform	148
NuPathe/ Teva	Company acquisition	Includes key product Zecuity [sumatriptan] for migraine	144**
Moderna Therapeutics/ Alexion Pharmaceuticals	Exclusive discovery and development	Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options	100
Cancer Prevention Pharmaceuticals/ Zeria Tillotts Pharma	Exclusive licensing agreement for Europe and Japan	The combination of CPP-1X/sulindac for the treatment of familial adenomatous polyposis (FAP an orphan disease)	100+
ACT Biotech/ Eddingpharm	Acquisition	Acquisition of 3 small molecule assets: Telatinib, a p3 ready VEGFr inhibitor for gastric cancer, ACTB1003, ACTB1010 (both p1 ready)	95
Horizon/ AZ	Collaboration and licence	Screening using siRNA platform for oncology drug targets	88
NantBioScience/ Celgene	Licence and option agreement	Nab [nanoparticle albumin bound] technology, option to protein kinases drug candidates, NTB-010, NTB-011	75
Living Proof/ Valeant	Development and commercialisation	Aesthetic dermatology products	75